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An Outbreak of Hemolytic Uremic Syndrome Associated
with Antibiotic Treatment of Hospital Inpatients for
Dysentery 
Shiga toxin (ST) from Shigella dysenteriae type
1 is accepted as a cause of hemolytic uremic syn-
drome (HUS); however, the reasons why HUS
develops in only some infected patients are not
clear (1). The possibility that antibiotic therapy is
associated with the development of HUS has been
explored for S. dysenteriae type 1 and for Es-
cherichia coli O157:H7 (2–4).  In May 1993, during
an outbreak of S. dysenteriae type 1 in Gizan,
Saudi Arabia, an association between antibiotic
treatment and HUS was also observed (5). The
strain of S. dysenteriae type 1 was resistant to
ampicillin, tetracycline, chloramphenicol, and
trimethoprim-sulfamethoxazole (TMP-SMX) and
sensitive to nalidixic acid. We report here some of
our preliminary observations for a concurrent out-
break.
In response to the Gizan outbreak, a circular
was sent to all regions of Saudi Arabia requesting
immediate reports of S. dysenteriae type 1. One
region reported three cases of S. dysenteriae type
1 with the same antibiotic resistance pattern. The
patients were visitors from the Najran region, on
the Yemen border. The affected family reported
that many other persons in their community of
Barshash, home of about 6,000 Yemeni immi-
grants, had recently had dysentery. The regional
hospital in Najran confirmed that several local
children had been treated for HUS, and an inves-
tigation was initiated.
Beginning in February 1993, the numbers of
dysentery patients at the Barshash Primary
Health Care Center began to increase from 6
patients per week to 110 in mid May. After control
measures were initiated, weekly incidence de-
creased to zero by late June. According to policy,
the Primary Health Care Center treated dysen-
tery patients with oral rehydration, whereas those
admitted to the regional hospital received antibi-
otics. At the regional hospital, S. dysenteriae type
1 was isolated from four Barshash residents and
one resident of another community. 
Between March and May, the illness of 10 (of
42) children admitted to the regional hospital for
dysentery progressed to HUS from 2 to 10 days
(median 5) after admission. For all 10 children,
physicians noted HUS onset as a sudden change
in the clinical condition characterized by pallor,
puffy face, peripheral edema, or oliguria. Within 2
days of clinical onset, blood urea nitrogen (BUN)
levels of all 10 children were 10 mmol/L. In nine
children, the hematocrit fell to below 75% of its
value on admission. One child had microcytic hy-
pochromic anemia on admission and was trans-
fused with one unit of packed red cells; his
hematocrit fell from 29.8% after the transfusion to
24.6% the day after HUS onset; his BUN level rose
from 3.1 to 23.5 mmol/L; and his thrombocyte
count fell from 529,000/mm3 to 75,000/mm
3. Red
cell fragments were reported for seven patients.
Thrombocytopenia, developed in seven patients;
in two, thrombocyte counts decreased from admis-
sion values. A leukemoid reaction (³ 30,000 leuko-
cytes/mm
3) developed in seven patients.
HUS cases included six children from Bar-
shash, one from a contiguous district, one with
relatives in Barshash, and two visiting from
southern Gizan region where the concurrent out-
break was occurring (5). No child was admitted
from the community with HUS. Reasons given for
admission were either dysentery or bloody diar-
rhea with mild or moderate dehydration. Two
dysentery patients who developed HUS were ad-
mitted because no one was available to care for
them at home. Characteristics on hospital admis-
sion of dysentery patients who did or did not
develop HUS were similar with the exception of
serum sodium level and BUN (Table 1). Elevations
in creatinine (63 to 133 mmol/L) and urea (6.1 to
7.9 mmol/L) levels on admission were mild, and
after intravenous rehydration returned to normal.
No enteric pathogens were isolated in stool speci-
mens from 35 patients.
All 42 dysentery patients received a variety of
antibiotic combinations composed of ampicillin,
TMP-SMX, nalidixic acid, gentamicin, erythromy-
cin, and metronidazole. Higher rates of HUS were
observed among patients receiving antibiotics to
which the locally circulating S. dysenteriae type 1
was resistant (ampicillin or TMP-SMX) or
antibiotics that are ineffective against Shigella
(metronidazole, erythromycin, gentamicin) than
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or without metronidazole) (Table 2). Stratification
of this analysis by elevated creatinine level (62
mmol/L) or BUN (6.0 mmol/L) on admission or by
weight for age above and below the fifth percentile
had no effect on the magnitude or statistical sig-
nificance of these associations. However, stratifi-
cation by serum sodium on admission above and
below 130 mmol/L yielded increased risk ratios of
15 (95% confidence interval, 1.6 to 147) for any
ineffective antibiotic and 15 (95% confidence
interval, 2.3 to 99) for ampicillin without nalidixic
acid (Mantel-Haentzel analysis).
These strong associations of HUS with prior
antibiotic therapy suggest that the antibiotics
may be influencing the progression of S. dysente-
riae type 1 to HUS (2,5). The Najran patients had
milder disease on admission, and the risk ratios
were higher than in the other two reports. The
assumption that S. dysenteriae type 1 caused the
dysentery is supported by the isolation of  S.
dysenteriae type 1 from community members
during a concomitant dysentery outbreak and by
the absence of other ST producing organisms.
However, because culture results are lacking, it is
possible that some hospitalized dysentery pa-
tients were infected with other organisms.
This investigation was retrospective, and with-
out randomization, the selection of patients for
treatment by severity of illness was managed with
stratified analysis. All possible indicators of dehy-
dration or severity of dysentery on admission were
not available for stratification. However, these
were also not available to the physicians for
selection of patients. Moreover, nalidixic acid was
considered effective therapy, and physicians did
not indicate in the medical records that they were
selecting nalidixic acid for less severely ill pa-
tients. Because of the variety of antibiotics pre-
scribed, the effect of antibiotics given to most
patients (metronidazole) in combination with
other antibiotics could not be evaluated. The
effectiveness of those given to a few patients
(TMP-SMX) could not be assessed.
Table 1. Characteristics on hospital admission of dysentery patients whose illness did or did not develop into hemolytic uremic
syndrome (HUS) during hospitalization, Najran, Saudi Arabia, March through May 1993
         Dysentery patients   
Characteristic Developed HUS (10) Did not develop HUS (32) p valuea
Age (yr mean) 4.4 4.8 0.71
Male sex 7 (70%) 23 (72%) 1.0
Percentile weight for age
b (median) 15.4 16.3 0.57
  Below fifth percentile  6 (60%) 12 (38%) 0.29
Days with dysentery (median) 3 3 0.70
 Range 2–8 1–14
Stools on first hospital day (median) 12.5 9.0 0.23
 Range 2–26 2–43
Temperature (mean) 38.2
oC3 8 . 0
o C 0.64
 Range 36.8
oC–39.4
oC3 6 . 5
o C–39.4
oC
Hematocrit (mean) 38.9% 38.8% 0.94
  Below 35.5% 4 (40%) 7 (23%) 0.43
Thrombocytes/mm
3 555,000 501,000 0.62
  Below 150,000 0 0
Leucocytes/mm
3 (mean) 11,440 12,300 0.62
  Above 12,000   7 (70%) 22 (69%) 1.0
  Above 18,000  1 (10%) 4 (13%) 1.0
Serum sodium, mmol/L (mean) 130 134 0.02
  Below 130 mmol/L  4 (40%) 7 (22%) 0.41
Serum potassium, mmol/L (mean) 3.4 3.4 0.86
  Below 3.5 mmol/L 5 (50%) 16 (50%) 1.0
Serum creatinine, mmol/L (mean) 72 62 0.62
  Above 62 mmol/L 5 (50%) 13 (41%) 1.0
BUN, mmol/L (mean) 4.1 3.2 0.06
  Above 6.0 mmol/L  2 (20%) 2 (6%) 0.24
aDifferences in means by Student’s t-test, in medians by the Kruskal-Wallis test, and in proportions by Fisher’s exact test (two-tailed). 
bNational Center for Health
Statistics.
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in various ways. The antibiotics given may have
been ineffective, so the infections were allowed to
run their natural course to HUS. However, one
would have expected at least a few cases to have
developed at home among the hundreds of
Barshash residents with dysentery. Another pos-
sibility is that ineffective antibiotics suppressed
competing microbial flora, allowing less re-
strained proliferation of  S. dysenteriae type 1.
This does not account for the 12% HUS attack rate
in patients treated with nalidixic acid. An in-vitro
study of enhanced Shiga-like toxin I (SLT-1) pro-
duction by E. coli O157:H7 suggests another ex-
planation. Subinhibitory concentrations of
antibiotics resulted in up to a 400% increase in
SLT-I recovery relative to controls (6). This effect
was maximal at maximum subinhibitory
concentrations of antibiotics, and a quinoline an-
tibiotic, ciprofloxacin,  yielded the greatest in-
crease of toxin. These findings are most consistent
with the epidemiologic findings in this outbreak,
including the occurrence of HUS in patients
treated with nalidixic acid and the absence of
HUS in untreated patients in the community.
With these considerations, antibiotic treatment of
dysentery from S. dysenteriae type 1 should be
approached with caution.
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Table 2. Risk of developing hemolytic uremic syndrome (HUS) by antibiotic combinations used for in-hospital treatment of
dysentery during a community outbreak of antibiotic-resistant Shigella dysenteriae type 1, Najran, Saudi Arabia, March through
May 1993
        Dysentery patients          95%
Developed Risk confidence
Antibiotic combination HUS (10) Total (42) HUS rate/100 ratio
a  interval
b
Ineffective
c antibiotics without nalidixic  6 12 50 4.3 1.3–15
 acid
d–j
Ampicillin combinations without nalidixic  5 7 71 6.2 1.9–20
 acid
d–f
Ineffective antibiotics without nalidixic acid  1  5 20 1.7 0.22–14
  or ampicillin
g–j
Ampicillin and nalidixic acid with (2) or without 1 3 33 2.9 0.40–20
 (3)  metronidazole
Trimethoprim-sulfamethoxazole,  nalidixic 
  acid and metronidazole 0 1 0 0
Nalidixic acid with (24) or without (2)
 metronidazole  (reference) 3 26 12 1.0 Reference
a Relative to the reference antibiotic combination (nalidixic acid with or without metronidazole). 
b Taylor series approximation standard. 
c Antibiotics to which the
outbreak strain of S. dysenteriae type 1 was resistant (ampicillin, trimethoprim-sulfamethoxazole) or which are ineffective against shigella (metronidazole, gentamicin,
or erythromycin). 
d Ampicillin and metronidazole (4 patients). 
e Ampicillin, metronidazole, and gentamicin (2 patients). 
f Ampicillin only (1 patient). 
g Trimethoprim-sul-
famethoxazole and metronidazole (1 patient). 
h Trimethoprim-sulfamethoxazole, erythromycin, and metronidazole (1 patient). 
i Metronidazole only (2 patients).
j Erythromycin and metronidazole (1 patient).
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